{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T09:38:31Z","timestamp":1794735511606,"version":"4.9.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009210","name":"Food and Drug Administration","doi-asserted-by":"publisher","award":["1R01FD003024-01"],"award-info":[{"award-number":["1R01FD003024-01"]}],"id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1053\/j.gastro.2008.02.014","type":"journal-article","created":{"date-parts":[[2008,2,15]],"date-time":"2008-02-15T07:36:24Z","timestamp":1203060984000},"page":"1360-1368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":562,"title":["A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome"],"prefix":"10.1053","volume":"134","author":[{"given":"Arun J.","family":"Sanyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"Garcia\u2013Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Regenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Rossaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Appenrodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Blei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit","family":"G\u00fclberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Sigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Teuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2008.02.014_bib1","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/hep.20687","article-title":"MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation","volume":"41","author":"Alessandria","year":"2005","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2008.02.014_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","article-title":"Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites","volume":"105","author":"Gines","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2008.02.014_bib3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jhep.2007.02.001","article-title":"Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome","volume":"46","author":"Arroyo","year":"2007","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2008.02.014_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0168-8278(86)80154-4","article-title":"Urinary excretion of 6-keto-prostaglandin F1 \u03b1, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites","volume":"3","author":"Rimola","year":"1986","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2008.02.014_bib5","first-page":"3185","article-title":"The hepatorenal syndrome","volume":"157","author":"Moller","year":"1995","journal-title":"Ugeskrift for laeger"},{"key":"10.1053\/j.gastro.2008.02.014_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199808203390807","article-title":"Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis","volume":"339","author":"Martin","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2008.02.014_bib7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/gut.49.5.729","article-title":"The hepatorenal syndrome","volume":"49","author":"Dagher","year":"2001","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2008.02.014_bib8","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1053\/gast.2002.33575","article-title":"Hepatorenal syndrome in cirrhosis: pathogenesis and treatment","volume":"122","author":"Arroyo","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2008.02.014_bib9","first-page":"1310","article-title":"Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis","volume":"56","author":"Salerno","year":"2007","journal-title":"A consensus workshop of the international ascites clubGut"},{"key":"10.1053\/j.gastro.2008.02.014_bib10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-2006-947293","article-title":"New treatments of hepatorenal syndrome","volume":"26","author":"Arroyo","year":"2006","journal-title":"Semin Liver Dis"},{"key":"10.1053\/j.gastro.2008.02.014_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2362.1975.tb02283.x","article-title":"Rregional and systemic haemodynamic effect of some vasopressins: structural features of the hormone which prolong activity","volume":"5","author":"Cort","year":"1975","journal-title":"Eur J Clin Invest"},{"key":"10.1053\/j.gastro.2008.02.014_bib12","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1007\/BF02088218","article-title":"Hepatorenal syndrome","volume":"41","author":"Ganne-Carrie","year":"1996","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2008.02.014_bib13","first-page":"2113","article-title":"Terlipressin may influence the outcome of hepatorenal syndrome complicating alcoholic hepatitis","volume":"92","author":"Cervoni","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2008.02.014_bib14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","article-title":"Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome","volume":"33","author":"Uriz","year":"2000","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2008.02.014_bib15","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/jhep.2002.35819","article-title":"Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study","volume":"36","author":"Ortega","year":"2002","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2008.02.014_bib16","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1440-1746.2002.02816.x","article-title":"Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis","volume":"17","author":"Colle","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2008.02.014_bib17","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/gast.2002.32364","article-title":"Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study","volume":"122","author":"Moreau","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2008.02.014_bib18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial","volume":"18","author":"Solanki","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2008.02.014_bib19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0168-8278(98)80151-7","article-title":"Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome","volume":"29","author":"Hadengue","year":"1998","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2008.02.014_bib20","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1365-2036.2006.03086.x","article-title":"Meta-analysis: terlipressin therapy for the hepatorenal syndrome","volume":"24","author":"Fabrizi","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2008.02.014_bib21","first-page":"164","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2008.02.014_bib22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1157\/13070705","article-title":"Circulatory support with albumin in liver cirrhosis","volume":"28","author":"Arroyo","year":"2005","journal-title":"Gastroenterologia y hepatologia"},{"key":"10.1053\/j.gastro.2008.02.014_bib23","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1111\/j.1572-0241.2000.03214.x","article-title":"Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors?","volume":"95","author":"Duhamel","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2008.02.014_bib24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2003.09.019","article-title":"Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome","volume":"40","author":"Restuccia","year":"2004","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2008.02.014_bib25","first-page":"78","article-title":"Terlipressin and gelafundin: safe therapy of hepatorenal syndrome","volume":"9","author":"Saner","year":"2004","journal-title":"Eur J Med Res"},{"key":"10.1053\/j.gastro.2008.02.014_bib26","first-page":"46","article-title":"Verbeke 2000: Linear mixed models for longitudinal data","author":"Verbeke","year":"2000"},{"issue":"Suppl 3","key":"10.1053\/j.gastro.2008.02.014_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2036.2004.02114.x","article-title":"Review article: hepatorenal syndrome\u2014how to assess response to treatment and nonpharmacological therapy","volume":"20","author":"Arroyo","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2008.02.014_bib28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1046\/j.1440-1746.2002.02778.x","article-title":"Hepatorenal syndrome in patients with cirrhosis","volume":"17","author":"Moreau","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2008.02.014_bib29","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/bega.2000.0140","article-title":"Diagnosis and treatment of hepatorenal syndrome","volume":"14","author":"Gines","year":"2000","journal-title":"Baillieres Best Pract Res Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2008.02.014_bib30","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis","volume":"8","author":"Schrier","year":"1988","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2008.02.014_bib31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0950-3528(97)90045-2","article-title":"Ascites and renal functional abnormalities in cirrhosis","volume":"11","author":"Gines","year":"1997","journal-title":"Baillieres Clin Gastroenterol"},{"issue":"Suppl D","key":"10.1053\/j.gastro.2008.02.014_bib32","first-page":"D112","article-title":"Update on peripheral arterial vasodilation, ascites and hepatorenal syndrome in cirrhosis","volume":"14","author":"Knotek","year":"2000","journal-title":"Can J Gastroenterol"},{"key":"10.1053\/j.gastro.2008.02.014_bib33","first-page":"15","article-title":"Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study","volume":"64","author":"Mulkay","year":"2001","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1053\/j.gastro.2008.02.014_bib34","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1111\/j.1572-0241.2005.00271.x","article-title":"Treatment of hepatorenal syndrome as defined by the International Ascites Club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study","volume":"100","author":"Peron","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2008.02.014_bib35","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jhep.2004.05.009","article-title":"Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"41","author":"Fernandez","year":"2004","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2008.02.014_bib36","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/hep.20829","article-title":"A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis","volume":"42","author":"Fernandez","year":"2005","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2008.02.014_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.510270107","article-title":"Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion","volume":"27","author":"Guevara","year":"1998","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2008.02.014_bib38","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/hep.510300430","article-title":"Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine","volume":"30","author":"Gulberg","year":"1999","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2008.02.014_bib39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2036.2003.01356.x","article-title":"Systematic review: terlipressin in acute oesophageal variceal hemorrhage","volume":"17","author":"Ioannou","year":"2003","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650850800245X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650850800245X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:36:46Z","timestamp":1762162606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001650850800245X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S001650850800245X"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2008.02.014","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2008.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2008.03.034","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 AGA Institute. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}